United States · FDA National Drug Code directory
LYTENAVA
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 82491-025_c4cac030-d1d8-4bb1-a38c-c1e2e91f002d
- Product NDC
- 82491-025
- Form
- INJECTION
- Composition / generic term
- bevacizumab-vikg
- Labeler
- Outlook Therapeutics, Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20260716
- Source listing expiry
- 20271231
Source-listed ingredients
- BEVACIZUMAB — 1.25 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 1 VIAL, GLASS in 1 CARTON (82491-025-10) / 1 INJECTION in 1 VIAL, GLASS · 82491-025-10
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →